文献速递造血干细胞移植与细胞治疗

抗CD4抗体调控移植物预防GVHD的新策略

Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation.
PubMed 文献 · Blood · 2026-01-01

异基因造血细胞移植后GVHD是主要并发症,现有免疫抑制剂全身非特异性作用带来毒性、感染和复发风险。本研究采用抗人CD4抗体MAX.16H5对移植物进行短期体外调控,通过功能实验和转录组分析揭示其机制为受损T细胞受体信号及向IL-10依赖调节表型偏移,单次孵育即可延长NSG小鼠生存并减轻GVHD表现,效果与重复使用临床免疫抑制剂相当。

要点

  • MAX.16H5短期体外调控移植物可诱导免疫耐受,有效预防GVHD。
  • 机制涉及TCR信号受损及向IL-10依赖调节表型偏移,减少CD4+和CD8+ T细胞活化增殖。
  • 单次孵育即延长NSG小鼠生存并减轻GVHD,效果与重复使用临床免疫抑制剂相当。

核心结论

  • 抗人CD4抗体MAX.16H5体外短期调控移植物是一种安全有效的GVHD预防免疫疗法。

研究设计与样本

  • 使用抗人CD4抗体MAX.16H5对造血细胞移植物进行短期体外调控,并通过功能体外实验和转录组分析评估机制,在NSG小鼠中验证效果。

主要发现

  • 功能体外实验和转录组数据提示T细胞受体信号受损及向IL-10依赖调节表型偏移,导致CD4+和CD8+ T细胞活化和增殖显著降低。
  • 单次孵育MAX.16H5延长NSG小鼠生存并减少GVHD表现,效果与重复应用临床免疫抑制剂相当。

临床怎么用

  • 该策略有望替代全身性免疫抑制剂,减少毒性、机会性感染和肿瘤复发风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) remains one of the major complications following allogeneic hematopoietic cell transplantation. Currently, immunosuppressants are used for GVHD prophylaxis and treatment in most transplantation recipients. Due to their systemic, nonspecific mode of action, this treatment regimen is frequently associated with severe toxic side effects, opportunistic infections, as well as cancer relapse when treating hematologic malignancies. By using short-term ex vivo modulation of hematopoietic cell transplants with the anti-human CD4 antibody MAX.16H5, we have developed a novel immune tolerance-inducing strategy enabling potent GVHD prevention. Functional in vitro assays and transcriptome profiling data suggest impaired T-cell receptor signaling and a shift toward an interleukin-10-dependent regulatory phenotype as the primary mechanism of action of anti-human CD4 antibody treatment, leading to significantly reduced activation and proliferation of CD4+ and CD8+ T cells. A one-time incubation of hematopoietic transplants with MAX.16H5 prolongs survival of NSG (NOD.Cg-PrkdcSCID Il2rgtm1Wjl/SzJ) mice and reduces signs of GVHD manifestation as effectively as repeated application with clinically applied immunosuppressants, making it a safe and effective immunotherapy for GVHD prevention.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Roth K, Loeffler D, Blumert C, et al. Anti-CD4 antibody-modulated transplants for GVHD prevention in hematopoietic cell transplantation. Blood. 2026. PMID: 41587074. doi:10.1182/blood.2025031370

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。